Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00954720 · ClinicalTrials.gov registry record
Observational Study of Iron Overload in Stem Cell Transplantation
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 45
- Enrollment target
NCT00954720: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT00954720 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00954720 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
Recent retrospective studies have suggested that iron overload is a clinically important problem in patients undergoing ablative stem cell transplantation. However, these studies relied on serum ferritin as a surrogate of iron overload, which limits the conclusions that can be drawn from such analyses. Therefore, the investigators are conducting a prospective study to more rigorously examine the prevalence, mechanisms, and consequences of iron overload in this patient population.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-05 |
What the finished NCT00954720 record still lists
NCT00954720 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT00954720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00954720 about?
NCT00954720 is a clinical study titled "Observational Study of Iron Overload in Stem Cell Transplantation". Recent retrospective studies have suggested that iron overload is a clinically important problem in patients undergoing ablative stem cell transplantation. However, these studies relied on serum ferritin as a surrogate of iron overload, which limits the conclusions that can be drawn from such analys...
What is the current status of trial NCT00954720?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2008-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00954720?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT00954720?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia